HLA class I antigen loss, tumor immune escape and immune selection.

Abstract excerpt

Poor clinical response rates have been observed in the majority of the T cell-based immunotherapy clinical trials conducted to date. One reason might be the presence of abnormalities in HLA class I antigen presentation in malignant lesions. An increased frequency of HLA class I abnormalities has been observed in malignant lesions from patients treated with T cell-based immunotherapy and in lesions which have...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Histocompatibility Antigens Class I
• Share to Immunotherapy
• Share to Mutation